INDEX

(January-December 1962)

A

Acatalasemia, carrier detection in, *Jan.*, 26
Acetyl strophanthidin
  dosage schedule, *Nov.*, 7
  duration of action, *Nov.*, 9
  test of digitalis tolerance, *Nov.*, 41 ff.
Achondroplasia, as genetic disease, *Jan.*, 4
Acromegaly
  clinical features, *Aug.*, 40 f.
  laboratory tests in, *Aug.*, 42
  treatment, *Aug.*, 42 f.
ACTH
  periodic, in corticosteroid therapy, *April*, 7 f.
  in regional enteritis, *March*, 26
  secretion
    in adrenal hyperplasia, *April*, 8
    corticosteroid effect on, *April*, 5 f.
    induced by mepyrapone, *April*, 20
Actinomycosis, pulmonary, *July*, 14
Addis test, in renal hypertension, *Dec.*, 5 f.
Adenoma
  acidophilic, in hypersomatotropism, *Aug.*, 35 f., 41, 43
  causing hyperaldosteronism, *April*, 28
Adenomatosis, pulmonary, *July*, 28
Adrenal cortex
  atrophy, *April*, 4 ff.
  hyperfunction, adrenalectomy in, *April*, 11
  hyperplasia
    congenital, *April*, 8 ff.
    DDD therapy, *April*, 16 ff.
  inhibition
    by corticosteroid-binding globulin in plasma, *April*, 10 f.
    methods, *April*, 3 ff.
    pharmacologic, *April*, 15 ff.
    physical methods, *April*, 11 ff.
    in therapy, *April*, 8, 10
  inhibitors, blocking agents as, *April*, 23 ff.
  insufficiency, in pituitary dwarfs, *Aug.*, 30
  regeneration after corticosteroid withdrawal, *April*, 6
Adrenal gland
  atrophy (idiopathic), *Sept.*, 16
  carcinoma, DDD therapy, *April*, 16 ff.
  tumors, with polycythemia, *June*, 52 f.
Adrenalectomy
  in breast and prostatic carcinoma, *April*, 13 f.
  chemical, *April*, 16 ff.
  in edema and sodium retention, *April*, 15
  for hyperfunction, *April*, 11 f.
  for hypertension, *April*, 12 f.
Adrenarche, premature, *Aug.*, 21
Adrenogenital syndrome, carrier detection in, *Jan.*, 26
Afibrinogenemia, carrier detection in, *Jan.*, 26
Agammaglobulinemia
  acquired, *May*, 27 ff.
    clinical findings, *May*, 29 ff.
    etiology, *May*, 27 ff.
  with arthritis, *Feb.*, 24
  classification, *May*, 13
  congenital, *May*, 14 ff.
    clinical findings, *May*, 22 ff.
    etiology, *May*, 14 ff.
  diagnosis, *May*, 33 ff.
  inheritance, *Jan.*, 32
  therapy, *May*, 36 ff.
Albinism, ocular, inheritance, *Jan.*, 31
Aldactone. *See* Spirolactone
Aldosterone
  chemical inhibitors of, *April*, 23 ff.
  pathophysiology of, *April*, 25 f.

INDEX

(January-December 1962)

A

Acatalasemia, carrier detection in, *Jan.*, 26
Acetyl strophanthidin
  dosage schedule, *Nov.*, 7
  duration of action, *Nov.*, 9
  test of digitalis tolerance, *Nov.*, 41 ff.
Achondroplasia, as genetic disease, *Jan.*, 4
Acromegaly
  clinical features, *Aug.*, 40 f.
  laboratory tests in, *Aug.*, 42
  treatment, *Aug.*, 42 f.
ACTH
  periodic, in corticosteroid therapy, *April*, 7 f.
  in regional enteritis, *March*, 26
  secretion
    in adrenal hyperplasia, *April*, 8
    corticosteroid effect on, *April*, 5 f.
    induced by mepyrapone, *April*, 20
Actinomycosis, pulmonary, *July*, 14
Addis test, in renal hypertension, *Dec.*, 5 f.
Adenoma
  acidophilic, in hypersomatotropism, *Aug.*, 35 f., 41, 43
  causing hyperaldosteronism, *April*, 28
Adenomatosis, pulmonary, *July*, 28
Adrenal cortex
  atrophy, *April*, 4 ff.
  hyperfunction, adrenalectomy in, *April*, 11
  hyperplasia
    congenital, *April*, 8 ff.
    DDD therapy, *April*, 16 ff.
  inhibition
    by corticosteroid-binding globulin in plasma, *April*, 10 f.
    methods, *April*, 3 ff.
    pharmacologic, *April*, 15 ff.
    physical methods, *April*, 11 ff.
    in therapy, *April*, 8, 10
  inhibitors, blocking agents as, *April*, 23 ff.
  insufficiency, in pituitary dwarfs, *Aug.*, 30
  regeneration after corticosteroid withdrawal, *April*, 6
Adrenal gland
  atrophy (idiopathic), *Sept.*, 16
  carcinoma, DDD therapy, *April*, 16 ff.
  tumors, with polycythemia, *June*, 52 f.
Adrenalectomy
  in breast and prostatic carcinoma, *April*, 13 f.
  chemical, *April*, 16 ff.
  in edema and sodium retention, *April*, 15
  for hyperfunction, *April*, 11 f.
  for hypertension, *April*, 12 f.
Adrenarche, premature, *Aug.*, 21
Adrenogenital syndrome, carrier detection in, *Jan.*, 26
Afibrinogenemia, carrier detection in, *Jan.*, 26
Agammaglobulinemia
  acquired, *May*, 27 ff.
    clinical findings, *May*, 29 ff.
    etiology, *May*, 27 ff.
  with arthritis, *Feb.*, 24
  classification, *May*, 13
  congenital, *May*, 14 ff.
    clinical findings, *May*, 22 ff.
    etiology, *May*, 14 ff.
  diagnosis, *May*, 33 ff.
  inheritance, *Jan.*, 32
  therapy, *May*, 36 ff.
Albinism, ocular, inheritance, *Jan.*, 31
Aldactone. *See* Spirolactone
Aldosterone
  chemical inhibitors of, *April*, 23 ff.
  pathophysiology of, *April*, 25 f.

Aldrich syndrome, genetic inheritance, *Jan.*, 41
Alleles, *Jan.*, 13
in germ cell formation, *Jan.*, 16 f.
multiple, *Jan.*, 19 f., 35 f.
pseudoalleles, *Jan.*, 37
Allergy
with auto-immune thyroiditis, *Sept.*, 16
to digitalis preparations, *Nov.*, 16
in etiology of regional enteritis, *March*, 7
genetic factors in, *Jan.*, 5
Amphenone
as adrenal inhibitor, *April*, 19 f.
sodium diuresis with, *April*, 19
Adrogens
adrenal, in adrenal hyperplasia, *April*, 8
for anemia of polycythemia, *June*, 40 f.
for dwarfism, *Aug.*, 35
in growth, *Aug.*, 20 f.
Anemia
in advanced polycythemia, *June*, 39 ff.
hemolytic
carrier detection in, *Jan.*, 26
as drug reaction, *Jan.*, 4
pernicious
detection methods, *Jan.*, 9
genetic factors in, *Jan.*, 7, 10
in regional enteritis, *March*, 13, 23
in rheumatoid arthritis, *Feb.*, 12
sickle cell, carrier detection, *Jan.*, 27, 29
Aneurysms, dissecting, of renal vessels, *Dec.*, 22
Angiokeratoma corporis diffusum, sex-linked inheritance, *Jan.*, 31
Antibodies
absence of, in agammaglobulinemias, *May*, 16 f., 27 f.
to second colloid antigen in thyroiditis, *Sept.*, 6
synthesis in dysgammaglobulinemia, *May*, 32
Anticoagulants, in polycythemia patients, *June*, 13
Antigens
colloid (second), in auto-immune thyroiditis, *Sept.*, 6
lymph-node response to, *May*, 12
in agammaglobulinemias, *May*, 24, 30
in thyroid disease, *Sept.*, 4, 12 f.
Anus, lesions in regional enteritis, *March*, 12, 18
Apnea, at birth, *Oct.*, 10 ff.
Appendicitis, acute, and enteritis, *March*, 14, 16, 18, 21
Arrhythmias
atrial
in digitalis excess, *Nov.*, 27 ff.
neostigmine test to predict digitalis dose, *Nov.*, 47 f.
atrioventricular nodal, in digitalis excess, *Nov.*, 30 ff.
digitalis-induced, *Nov.*, 19 ff.
carotid sinus stimulation in diagnosis, *Nov.*, 30, 39 f.
differentiation with EDTA, *Nov.*, 45
mortality from, *Nov.*, 6
procaine amide for, *Nov.*, 51 f.
treatment with EDTA, *Nov.*, 44 f., 52
potassium chloride in, *Nov.*, 49 f.
as digitalis tolerance test, *Nov.*, 46 f.
supraventricular, quinidine in, *Nov.*, 27
ventricular, in digitalis excess, *Nov.*, 35 ff.
Arteriography, renal, *Dec.*, 11
effect on blood pressure level, *Dec.*, 14
indications for, *Dec.*, 15, 21
methods, *Dec.*, 8
in unilateral disease diagnosis, *Dec.*, 8
Arteritis, in rheumatoid arthritis, *Feb.*, 7, 8, 10
Arthritis
agammaglobulinemic, relation to rheumatoid, *Feb.*, 24 f.
experimental, *Feb.*, 38 f.
rheumatoid
and agammaglobulinemia, *Feb.*, 24 f., *May*, 25 f.
with auto-immune thyroiditis, *Sept.*, 15
clinical picture, *Feb.*, 9 ff.
detection method in, *Jan.*, 9

Arthritis—*Cont'd*
diagnostic criteria, *Feb.*, 14 ff.
diseases related to, *Feb.*, 17 ff., 24 f.
drug therapy, *Feb.*, 40 ff., 44 ff.
familial incidence of, *Feb.*, 37
findings excluding diagnosis of, *Feb.*, 15 f.
generalized nature of, *Feb.*, 5 ff.
juvenile, *Feb.*, 13 f.
L. E. factor in, *Feb.*, 35 ff.
management, *Feb.*, 39 ff.
pathology, *Feb.*, 3 ff.
population studies of, *Feb.*, 36 ff.
rheumatoid factor in, *Feb.*, 18, 26 ff. tests for, *Feb.*, 28
surgical procedures in, *Feb.*, 53 f.
Ascariasis, pulmonary, *July*, 16, 18
Aspergillosis, pulmonary, *July*, 14
Asphyxia, in newborn, *Oct.*, 11
Atherosclerosis
genetic factors in, *Jan.*, 5, 7
renal artery, *Dec.*, 22
hypertension from, *Dec.*, 10
Atrium, ectopic premature beats, *Nov.*, 38
Auto-antibodies, thyroid
detection methods, *Sept.*, 4 ff.
in diagnosis of auto-immune thyroiditis, *Sept.*, 16 f.
discovery of, *Sept.*, 4
formation, in thyroiditis, *Sept.*, 12 f.
Auto-immunity
mechanism in adrenal atrophy, *Sept.*, 16
role in thyroiditis, *Sept.*, 12 f.

B

Bacitracin, in neonatal infections, *Oct.*, 25 f.
Bacterial infections
in hypogammaglobulinemias, *May*, 14, 16 f., 22 f., 29 f., 31, 33
of lung, *July*, 13, 16, 17
in newborn, *Oct.*, 24 ff.
Behavioral disorders, genetic factors in, *Jan.*, 5
Beryllium disease
pulmonary, *July*, 23 ff.
skin test in, *July*, 38
Blastomycosis, North American, *July*, 15
Blindness
from digitalis excess, *Nov.*, 18
in prematures, *Oct.*, 14 f.
Blood
arterial oxygen saturation and polycythemia, *June*, 18, 44
coagulation disorders, carrier detection in, *Jan.*, 26 f.
groups
and antigenic determinants of micro-organism, *Jan.*, 50
inheritance, *Jan.*, 36, 37
prenatal selection in, *Jan.*, 51
platelets in polycythemia, *June*, 19 f.
pressure levels in renal hypertension, *Dec.*, 14
rheumatoid factor, *Feb.*, 18, 26 ff.
values in polycythemia, *June*, 15 ff., 47 f.
vessels (small), lesions in rheumatoid arthritis, *Feb.*, 7, 8, 10
Blood transfusion
causing hemosiderosis, *July*, 27
exchange, digitalis in, *Oct.*, 22
Body measurements
differential growth equation, *Oct.*, 8, 10
in drug dose calculations, *Oct.*, 6 ff.
height as index of growth, *Aug.*, 23 f.
Bone
diseases, growth retardation in, *Aug.*, 31
distortion in acromegaly, *Aug.*, 40
growth hormone effect on, *Aug.*, 17 f.
maturation
as index of growth, *Aug.*, 24 f.
premature, *Aug.*, 32
Bone marrow
hyperplastic states, *June*, 5 f.
in polycythemia, *June*, 8, 24 f., 48
suppressants
in polycythemia, *June*, 28 ff.
in thrombocythemia, *June*, 42
Brachyphalangy, of index finger, *Jan.*, 20

Breast carcinoma
adrenalectomy in, *April*, 13 f.
pulmonary metastases, *July*, 29
Bronchiolitis
in infants, digitalis in, *Oct.*, 21
occupational, *July*, 25
Bronchopneumonia
secondary to viral disease, *July*, 19
x-ray shadows in, *July*, 10
Bruit, epigastric, in renal hypertension, *Dec.*, 15, 21
Busulfan
in polycythemia, *June*, 30, 34, 41
in thrombocythemia, *June*, 42

C

Caffeine
genetic mutations due to, *Jan.*, 44
use in infants, *Oct.*, 12, 13
Calcium
chelation in digitalis-induced cardiotoxicity, *Nov.*, 44 ff.
-digitalis tolerance test, *Nov.*, 46
inhaled, causing miliary shadows, *July*, 23
role in digitalis intoxication, *Nov.*, 15
serum, growth hormone effect on, *Aug.*, 17
with steroids in arthritis, *Feb.*, 51
Cancer
somatic cell genetics and, *Jan.*, 6
of stomach, genetic factors in, *Jan.*, 7
thyroid, differentiated from autoimmune thyroiditis, Sept., 21 f.
Carbohydrate metabolism, growth hormone effect on, *Aug.*, 14, 16
Carcinoma
adrenocortical
amphenone in, *April*, 19
DDD therapy, *April*, 16 ff.
breast, adrenalectomy in, *April*, 13 f.
bronchial, *July*, 28, 31
polycythemia with, *June*, 50 ff.
prostatic, adrenalectomy in, *April*, 13 f.
pulmonary metastatic, *July*, 29 ff.
Carcinomatosis
hematogenous, *July*, 29 f.
lymphangitic, *July*, 29
Carotid sinus
pressure, in differentiating atrial flutter and tachycardia, *Nov.*, 29, 30
sensitivity, with digitalis, *Nov.*, 16
stimulation, to determine state of digitalization, *Nov.*, 39 ff., 43
Cells
blood, chromosomal abnormality, *Jan.*, 6
chromosomal somatic mutation in, *Jan.*, 43
deficiency, in agammaglobulinemias, *May*, 18 f., 29
genetic apparatus, *Jan.*, 10 ff.
mosaic, *Jan.*, 13
protein synthesis in, *Jan.*, 11
sperm and egg formation, *Jan.*, 15 f.
Cerebellum, tumors with polycythemia, *June*, 54
Chemicals
as adrenal inhibitors, *April*, 4, 15 ff.
genetic mutations from, *Jan.*, 44, 46
marrow-suppressant, in polycythemia, *June*, 33 f.
Chloramphenicol, in neonatal infections, *Oct.*, 26 ff.
Chloroquine, in rheumatoid arthritis, *Feb.*, 46
Cholesterol synthesis, effect of triparanol, *April*, 23
Chondrohypoplasia, dominant inheritance of, *Jan.*, 20
Chorea, Huntington's, as genetic disease, *Jan.*, 4
Choroideremia, inheritance, *Jan.*, 31
Chromosomes
abnormalities causing genetic disease, *Jan.*, 4 f., 6
autosomal, in inheritance, *Jan.*, 17 ff., 32
deletions or deficiencies, *Jan.*, 13
duplications, *Jan.*, 13 f.
gene loci on, *Jan.*, 12 f.
meiosis, *Jan.*, 15 ff.
nature and function, *Jan.*, 10 ff.

Chromosomes—*Cont'd*
number in man, *Jan.*, 10, 15
sex, hereditary traits carried by, *Jan.*, 30 ff.
translocations in, *Jan.*, 13
visible mutations, *Jan.*, 13, 41, 43
Cirrhosis
alcoholic, detection of patient susceptibility, *Jan.*, 7
auto-immune thyroiditis with, *Sept.*, 15 f.
edema of, aldosterone antagonist for, *April*, 27, 28 f.
Cobalt ingestion, and polycythemia, *June*, 55
Coccidioidomycosis
pulmonary, *July*, 15
skin test in, *July*, 38
Colistimethate, in infections of newborn, *Oct.*, 28 f.
Colitis, ulcerative, differentiated from enteritis, *March*, 12 f., 21 f.
Collagen. *See* Connective tissue
Color blindness, inheritance, *Jan.*, 31, 37
Connective tissue
changes in rheumatoid arthritis, Feb., 25 f.
disease
with agammaglobulinemia, *May*, 25 f.
with auto-immune thyroiditis, *Sept.*, 15
pulmonary involvement, *July*, 25 ff.
relation to rheumatoid arthritis, *Feb.*, 17 ff.
growth hormone effect on, *Aug.*, 17 f.
proliferation in acromegaly, *Aug.*, 40
Consanguinity
in family history, *Jan.*, 53
in recessive inheritance, *Jan.*, 23
Contrast mediums, retention in lungs, *July*, 36 f.
Corticosteroids
ACTH-suppressing potencies, *April*, 6
for adrenal hyperplasia, *April*, 8
as adrenal inhibitor, *April*, 3, 4 ff.
-binding globulin, *April*, 10 f.
defect in formation, *April*, 8 f.
excess, and growth, *Aug.*, 21
for idiopathic hirsutism, *April*, 10
inhibitors of synthesis, April, 19 ff.
in irradiation pneumonitis, *July*, 32
with mepyrapone administration, *April*, 21
for metastatic carcinoma of breast, *April*, 14
for polyarteritis nodosa, *July*, 26
regimen in patients requiring surgery, *April*, 6 ff.
in regional enteritis, *March*, 24 ff.
in rheumatoid arthritis, *Feb.*, 48 ff.
intra-articularly, *Feb.*, 52 f.
Cortisol, normal adrenal production, *April*, 5
Cortisone
ACTH-suppressing potency, *April*, 5
in experimental cleft palate, *Jan.*, 5
Craniopharyngioma, causing pituitary insufficiency, *Aug.*, 27
Cretinism, goitrous, *Jan.*, 39
carrier detection in, *Jan.*, 26
Crohn's disease. *See* Enteritis, regional
Cushing's syndrome
adrenalectomy in, *April*, 11 f.
DDD in therapy, *April*, 16 f.
and polycythemia, *June*, 52 f.
Cyanosis, therapy in newborn, *Oct.*, 15 f.
Cystinosis, carrier detection in, *Jan.*, 26
Cystinuria, dominant inheritance of, *Jan.*, 20

D

DDD
as adrenal inhibitor, *April*, 4, 15 ff.
dosage in adrenal carcinoma, *April*, 17
side effects, *April*, 18
Dermatomyositis
with agammaglobulinemia, *May*, 27

relation to rheumatoid arthritis, *Feb.*, 18, 20
Desoxyribose nucleic acid
of chromosomes, *Jan.*, 10 ff.
function, *Jan.*, 11
effects of alteration, *Jan.*, 13 ff.
Dexamethasone, ACTH-suppressing potency, *April*, 5 f.
Diabetes insipidus, sex-linked inheritance, *Jan.*, 31
Diabetes mellitus
carrier frequency, *Jan.*, 25
genetic factors in, *Jan.*, 6, 7
growth hormone effects in, *Aug.*, 16
Diarrhea, in regional enteritis, *March*, 14, 18, 23, 31
Digitalis glycosides
absorption and distribution, *Nov.*, 8
contraindications, *Nov.*, 53
dosage safeguards, *Nov.*, 55 f.
dosage schedules, *Nov.*, 7, 8
in newborn, *Oct.*, 23 f.
effect on electrocardiographic findings, *Nov.*, 20 f.
effect in patients receiving reserpine, *Nov.*, 40
general safeguards in use, *Nov.*, 54 ff.
history of, *Nov.*, 3 f.
in newborn, *Oct.*, 21 ff.
nonindications for, *Nov.*, 53
overdosage
absolute, *Nov.*, 11 f.
cumulative, *Nov.*, 12
relative, *Nov.*, 12 ff.
pharmacology, *Nov.*, 6 ff.
potassium given with, *Nov.*, 50
preparations, *Nov.*, 7, 55
prophylactic use, *Nov.*, 54
routes of administration, *Nov.*, 55
side effects, *Nov.*, 10, 16 f.
use in population, *Nov.*, 5
withdrawal, in toxicity, *Nov.*, 48 f.
Digitalis intoxication
cardiac manifestations, *Nov.*, 19 ff.
diagnostic tests, *Nov.*, 39 ff.
duration of stigmata, *Nov.*, 8
extracardiac manifestations, *Nov.*, 17 ff.
incidence, *Nov.*, 4 ff.
incipient, diagnosis, *Nov.*, 40
intrauterine, *Nov.*, 12
management, *Nov.*, 48 ff.
in newborn, *Oct.*, 22
predisposing factors in, *Nov.*, 56 ff.
prevention, *Nov.*, 52 f., 54 ff.
progressive signs of, *Nov.*, 35, 37
"regularization of rhythm" in, *Nov.*, 32, 35
Digitalis leaf
dosage schedule, *Nov.*, 7
duration of action, *Nov.*, 9
Digitoxin
dosage schedule, *Nov.*, 7
duration of action, *Nov.*, 9
in infants, *Oct.*, 23 f.
Digoxin
dosage schedule, *Nov.*, 7
duration of action, *Nov.*, 9
in infants, *Oct.*, 23
toxicity in newborn, *Oct.*, 22
Distomiasis, pulmonary, *July*, 18
Diuretics
potassium with, *Nov.*, 50, 57
withdrawal, with digitalis withdrawal, *Nov.*, 49
DNA. *See* Desoxyribose nucleic acid
Drugs
absorption and transport, in infants, *Oct.*, 43
calculation of a dose, *Oct.*, 6 ff.
factors in pharmacologic action, *Oct.*, 4 ff., 43 ff.
in newborn, *Oct.*, 3 ff.
reactions, genetic-environmental factors, *Jan.*, 4
toxicity
factors determining, *Oct.*, 5
variations in newborn, *Oct.*, 43
see also specific agents
Dwarfism
achondroplastic, incidence, *Jan.*, 41
etiologic classification, *Aug.*, 31 f.
pituitary, *Aug.*, 27 ff.
treatment, *Aug.*, 34 f.
primordial, *Aug.*, 31, 32 f.
Dysgammaglobulinemia
classification, *May*, 13, 31
clinical findings, *May*, 32
diagnosis, *May*, 33 ff.

Dysgammaglobulinemia—*Cont'd*
therapy, *May*, 36 ff.
Dyshormonogenesis, diagnosis, *Sept.*, 23
Dystrophy, muscular, inheritance, *Jan.*, 21, 32, 39

E

Ectodermal dysplasia, inheritance, *Jan.*, 31
Edema
anti-aldosterone drugs in, *April*, 27
with sodium retention, adrenalectomy in, *April*, 15
Electrocardiography, to detect digitalis excess, *Nov.*, 19 ff.
Electrophoresis
in agammaglobulinemia, *May*, 36
in diagnosis of thyroid disorders, *Sept.*, 17, 21
Elliptocytosis, inheritance of, *Jan.*, 20, 39
Endocrine disturbances, and growth, *Aug.*, 32, 33
Enteritis
bacterial, in newborn, *Oct.*, 32
E. coli, in newborn, *Oct.*, 29, 32
Enteritis, regional
"acute," *March*, 8, 13
clinical findings, *March*, 13 ff.
complications, *March*, 16 ff.
diagnostic features, *March*, 18 ff.
differential diagnosis, *March*, 12 f., 20 ff.
etiologic concepts, *March*, 5
incidence, *March*, 3 f.
medical therapy, *March*, 22 ff., 31
pathogenesis, *March*, 4 ff.
pathology, *March*, 8 ff.
recurrences, *March*, 30 ff.
after surgery, *March*, 28 f.
roentgen diagnosis, *March*, 19 f.
surgical treatment, *March*, 26 ff.
Environment
factors in disease susceptibility, *Jan.*, 7 ff.
role in disease etiology, *Jan.*, 4 f.
Enzymes
deficiency
in adrenal hyperplasia, *April*, 8
and drug reaction, *Jan.*, 4
genetic control of, *Jan.*, 12
reactions, and single gene mutations, *Jan.*, 14
Eosinophilia, tropical, *July*, 16
Epinephrine, use in infants, *Oct.*, 13
Erythremia. *See* Polycythemia vera
Erythrocytes
hemagglutination test for thyroid auto-antibodies, *Sept.*, 5 f., 17, 20 f.
in polycythemia, *June*, 15 ff., 38 f.
sedimentation in auto-immune thyroiditis, *Sept.*, 18
Erythromycin, for infections of newborn, *Oct.*, 29 ff.
Estrogens, in growth, *Aug.*, 21
Ethylene-diamine-tetra-acetate, in digitalis-induced arrhythmias, *Nov.*, 44 ff., 52
Exercise, in rheumatoid arthritis, *Feb.*, 44
Eyes
lesions in rheumatoid arthritis, *Feb.*, 13
see also Blindness, Vision

F

Family history
genetic aspects, *Jan.*, 52 ff.
in polycythemia, *June*, 5
in regional enteritis, *March*, 4
in rheumatoid arthritis, *Feb.*, 36 ff.
Farmer's lung, *July*, 23, 25
Fat metabolism, growth hormone effect on, *Aug.*, 14, 15 f.
Felty's syndrome, and rheumatoid arthritis, *Feb.*, 8, 10, 13
Feminization syndrome, inheritance, *Jan.*, 31
Fibrillation, atrial
digitalis effects in, *Nov.*, 22, 26
digitalis-induced, *Nov.*, 27, 30
Fibrinogen, in polycythemia, *June*, 20 f.
Fibrosis
chronic diffuse interstitial, *July*, 34
cystic
carrier detection in, *Jan.*, 26
carrier frequency in, *Jan.*, 25
of renal artery, *Dec.*, 22

Filariasis, pulmonary, *July*, 18
Fistula, in regional enteritis, *March*, 9, 11, 15, 16
Flank pain, in renal hypertension, *Dec.*, 15 f., 21
Fluid
  loss, polycythemia from, *June*, 56
  therapy, in newborn, *Oct.*, 19 ff.
Fluorohydrocortisone, in polycythemia, *June*, 35
Flutter, atrial, *Nov.*, 28
  with digitalis excess, *Nov.*, 28
Foreign bodies, in etiology of regional enteritis, *March*, 6 f.
Frostbite, detection methods, *Jan.*, 8
Fungal infections, of lung, *July*, 13, 14 f.

G

Galactosemia, carrier detection in, *Jan.*, 26
Gamma globulin
  antibodies to thyroglobulin, *Sept.*, 5
  deficiencies, *see* Hypogammaglobulinemias; specific entities
  metabolism of, *May*, 7 ff.
  plasma concentration, *May*, 9
    in defects, *May*, 33 ff.
  pooled, in therapy, May, 36 f.
  properties of, *May*, 5 f.
  rate of degradation, *May*, 9 ff.
  rheumatoid factor in, *Feb.*, 26 ff.
  synthesis
    rate of, *May*, 11 f.
    types of defects, *May*, 31 f.
  terminology, *May*, 6 f.
  thyroid cytotoxic factor in, *Sept.*, 7
Gastrointestinal tract
  symptoms in digitalis intoxication, *Nov.*, 17 f.
  symptoms in enteritis, *March*, 13, 21
Gaucher's disease, detection methods, *Jan.*, 8
Genes
  controller, *Jan.*, 11
  crossing-over of, *Jan.*, 15
  defined, *Jan.*, 11
  dominant, *Jan.*, 17 ff.
    diseases due to, *Jan.*, 18, 19, 20
  expressivity of, *Jan.*, 19
  linkage of, *Jan.*, 35 ff.
  loci on chromosomes, *Jan.*, 12 f.
  mutations, *Jan.*, 13 f., 41 ff.
    in disease inheritance, *Jan.*, 22
    in recessive inheritance, *Jan.*, 22 f.
  pleiotropism, *Jan.*, 37, 40
  quantitative effects in inheritance, *Jan.*, 33 ff.
  regulator, *Jan.*, 11
  sex-linked, *Jan.*, 30 ff.
  symbols for, *Jan.*, 12 f.
Genetics
  in disease etiology, *Jan.*, 4 f.
    predisposing factors, *Jan.*, 6 ff.
    and therapy, *Jan.*, 6 ff.
  factor in auto-immune thyroiditis, *Sept.*, 15
  factor in essential hypertension, *Dec.*, 12 f.
  and family history, *Jan.*, 52 ff.
  glossary of terms, *Jan.*, 57 ff.
  in growth patterns, *Aug.*, 27, 32
  Hardy-Weinberg law, *Jan.*, 47
  heterogeneity in, *Jan.*, 38 ff.
  law of independent assortment, *Jan.*, 17
  law of segregation, *Jan.*, 16
  natural selection and, *Jan.*, 50 f.
  and physiologic characteristics, *Jan.*, 6
  population, *Jan.*, 47 ff.
  role in disease susceptibility, *Jan.*, 7 ff.
  somatic cell, *Jan.*, 6
Genocopy, *Jan.*, 41
Genotypes, distribution in population, *Jan.*, 47 ff.
Gigantism, pituitary, *Aug.*, 35 ff.
Gitalin
  dosage schedule, *Nov.*, 7
  duration of action, *Nov.*, 9
Globulins
  electrophoretic fractions of, *May*, 5 f.
  see also Gamma globulin
Glomerulonephritis, with hemosiderosis, *July*, 27
Glucose-6-phosphatase, deficiency in glycogen storage disease, *Jan.*, 26

Glucose-6-phosphate dehydrogenase deficiency
drug reaction in, *Jan.*, 4
and resistance to malaria, *Jan.*, 5
sex-linked inheritance, *Jan.*, 31
Glycogen storage disease, *Jan.*, 39
carrier detection in, *Jan.*, 26
Goiter
drug-induced, *Sept.*, 23 f.
lymphadenoid, *see* Thyroiditis, auto-immune
nontoxic, detection methods, *Jan.*, 9
simple, differentiated from auto-immune thyroiditis, *Sept.*, 20
Gold salts
in rheumatoid arthritis, *Feb.*, 47 f.
in rheumatoid-related diseases, *Feb.*, 54, 55
Gonads, influence on growth, *Aug.*, 20 f.
Gout
detection method, *Jan.*, 8
heredity and, *Jan.*, 4
Granuloma
in regional enteritis, *March*, 6, 11
rheumatoid, *Feb.*, 5
Granulomatosis, Wegener's, *July*, 26
Growth
developmental vs. chronological age as measure, *Aug.*, 25 f.
equation (differential), *Oct.*, 10
in drug dose calculation, *Oct.*, 8
hormonal regulation, *Aug.*, 18 ff.
normal, characteristics of, *Aug.*, 23 ff.
retardation, etiologic classification, *Aug.*, 31 f.
skeletal, effect of tetracyclines in prematures, *Oct.*, 42
Gynecomastia, from digitalis preparations, *Nov.*, 16

H

Hamman-Rich syndrome, *July*, 34
Hardy-Weinberg law, in population genetics, *Jan.*, 47
Hashimoto's thyroiditis. *See* Thyroiditis, auto-immune
Headache, in polycythemia, *June*, 9, 32
Heart
block
antegrade, *Nov.*, 32 ff.
atrioventricular, with digitalis, *Nov.*, 21, 23 ff., 28
digitalis contraindicated, *Nov.*, 53
retrograde, *Nov.*, 33, 35
congestive failure
digitalis glycosides in, *Nov.*, 5 ff.
in infants, digitalis for, *Oct.*, 21 f.
spirolactone in, *April*, 30
defects, and anoxic polycythemia, *June*, 44 ff.
digitalis effects on, *Nov.*, 13, 21 ff.
effects of digitalis intoxication, *Nov.*, 19 ff.
inflammatory changes in arthritis, *Feb.*, 5 f., 12
murmur, in rheumatoid arthritis, *Feb.*, 12
output, in polycythemia, *June*, 15
rate, digitalis effect on, *Nov.*, 21 ff.
Heat intolerance, in polycythemia, *June*, 10
Height, as index of growth, *Aug.*, 23 f.
Hemagglutination inhibition, in growth hormone assay, *Aug.*, 7 f.
Hemochromatosis
detection methods, *Jan.*, 8
dominant inheritance, *Jan.*, 20
Hemoglobin
abnormalities, therapy in, *Jan.*, 10
diaphorase deficiency, *Jan.*, 26
C disease, carrier detection in, *Jan.*, 26
sickle cell, *Jan.*, 27, 29
Hemophilia, heredity in, *Jan.*, 4, 31
Hemorrhage
with pituitary tumors, *Aug.*, 36
in polycythemia, *June*, 12
Hemosiderosis
with cardiovascular disorders, *July*, 27 f.
idiopathic, involving lung, *July*, 27
Heredity. *See* Inheritance

Hirsutism
in adrenal hyperplasia, *April*, 8
idiopathic, in female, *April*, 8 ff.
Histiocytosis
causing growth retardation, *Aug.*, 27
involving lungs, *July*, 36
Histoplasmosis
pulmonary features, *July*, 14
skin test in, *July*, 38
Hodgkin's disease, pulmonary x-ray findings, *July*, 31
Hormone
growth
measurement of, *Aug.*, 6 ff.
metabolism of, *Aug.*, 10 ff.
nature of, *Aug.*, 4 ff.
physiologic actions, *Aug.*, 13 ff., 18 f.
species-specificity, *Aug.*, 5
in treatment of dwarfism, *Aug.*, 34 f.
therapy, in acromegaly, *Aug.*, 43
see also specific hormones
Hyaline membrane disease
digitalis in, *Oct.*, 22
in newborn, *Oct.*, 13, 15 f.
Hydrarthrosis, intermittent, *Feb.*, 25
Hyperaldosteronism, therapy, *April*, 27 f.
Hypercholesteremia, dominant inheritance, *Jan.*, 20
Hypergammaglobulinemia, with auto-immune thyroiditis, *Sept.*, 17
Hyperlipemia, dominant inheritance, *Jan.*, 20
Hypersomatotropism
causes, *Aug.*, 35 f.
clinical results, *Aug.*, 36 ff.
treatment, *Aug.*, 42 f.
Hypertension
adrenalectomy for, *April*, 12 f.
age of development in differential diagnosis, *Dec.*, 12
aldosterone role in, *April*, 26, 28
detection methods, *Jan.*, 8
genetic factors, *Jan.*, 5, 8
intravenous urography in patients with, Dec., 16 ff.
malignant, *Dec.*, 14, 15, 21
features suggesting, *Dec.*, 15
renal artery lesions in, *Dec.*, 19
in polycythemia, *June*, 14
pulmonary, with hemosiderosis, *July*, 27
pyelonephritic, *Dec.*, 4
renal, *Dec.*, 10 ff.
angiography in, *Dec.*, 21
from atherosclerosis, *Dec.*, 10
clinical features, *Dec.*, 12 ff.
differential diagnostic tests, *Dec.*, 5 ff.
medical treatment and results, *Dec.*, 25 ff.
mortality in, *Dec.*, 25, 27
surgery in, *Dec.*, 22 ff.
Hypogammaglobulinemias
classification, *May*, 13 ff.
diagnosis, *May*, 33 ff.
therapy, *May*, 36 ff.
transient, *May*, 30
Hypoglycemia, familial, *Jan.*, 26
Hypogonadism, in pituitary dwarfs, *Aug.*, 30
Hypokalemia, in renal artery disease, *Dec.*, 15, 16
Hypophosphatasia, carrier detection in, *Jan.*, 26
Hypophysectomy, in breast cancer, *April*, 13
Hypopituitarism, mepyrapone test in diagnosis, *April*, 21 f.
Hypopotassemia, in digitalis intoxication, *Nov.*, 49
Hyposomatotropism. *See* Dwarfism
Hypotension, orthostatic, in renal hypertension, *Dec.*, 14 f.
Hypothyroidism
in auto-immune thyroiditis, *Sept.*, 14, 15
with pituitary dwarfism, *Aug.*, 28
primary, and auto-immune thyroiditis, *Sept.*, 24 f.
in thyrotoxicosis, *Sept.*, 26
Hypoxemia, with polycythemia, *June*, 42
Hypoxia, with polycythemia, *June*, 46

I

Idiocy, infantile amaurotic, carrier detection in, *Jan.*, 26
Ileitis
backwash, *March*, 12
see also Enteritis, regional
Immunity. *See* Auto-immunity

Infants
newborn
antimicrobial agents in, *Oct.*, 24 ff.
digitalis in, *Oct.*, 21 ff.
fluid and electrolyte therapy in, *Oct.*, 19 ff.
oxygen therapy in, *Oct.*, 14 ff.
stimulants in, *Oct.*, 10 ff.
vitamin K in, *Oct.*, 17 ff.
stimulants for, *Oct.*, 13
variables in drug effects in, *Oct.*, 5, 43 ff.
Infection
in etiology of regional enteritis, *March*, 5 f.
genetic factors in resistance to, *Jan.*, 5
pulmonary, causing miliary shadowing, *July*, 13 ff.
recurrent, in hypogammaglobulinemias, *May*, 14, 16 f., 22 f., 29 f., 33
Influenza, pulmonary involvement, *July*, 21
Inheritance
autosomal dominant, *Jan.*, 17 ff.
modification of, *Jan.*, 21
autosomal recessive, *Jan.*, 22 ff.
carrier state in, *Jan.*, 25 ff.
basic patterns of, *Jan.*, 17 ff.
of disease, *Jan.*, 4 f.
phenomenon of anticipation, *Jan.*, 21
of gamma globulin deficiencies, *May*, 20 f., 29
heterogeneity in genetic transmission, *Jan.*, 38 ff.
polygenic, *Jan.*, 33 ff.
sex-limited, *Jan.*, 32
sex-linked, *Jan.*, 30 ff.
recessive, *Jan.*, 29, 30 ff., *May*, 20
transmission of genes, *Jan.*, 15 ff.
Insulin
and growth maintenance, *Aug.*, 21 f.
resistance in hypersomatotropism, *Aug.*, 42
Iodide goiter, *Sept.*, 23
Iodine metabolism
in auto-immune thyroiditis, *Sept.*, 18 f., 21
inborn errors of, *Sept.*, 23
Iron
depletion, with phlebotomy, *June*, 28, 42, 50
serum, in polycythemia, *June*, 21 ff.
Isoalleles, *Jan.*, 19, 21, 36

J

Jaundice
congenital nonhemolytic, carrier detection in, *Jan.*, 26
neonatal, from vitamin K, *Oct.*, 17 ff.
Joints
corticosteroid injection into, in arthritis, *Feb.*, 52 f.
splinting of, in arthritis, *Feb.*, 44
surgical procedures on, in arthritis, *Feb.*, 53 f.

K

Kanamycin, for injections of newborn, *Oct.*, 31 f.
Keratoconjunctivitis sicca, relation to rheumatoid arthritis, *Feb.*, 18, 21
Kernicterus, neonatal, vitamin K role in, *Oct.*, 15 ff.
Kidney
arterial disease
causes and types of, *Dec.*, 3 f.
classification, *Dec.*, 21 f.
indications for angiography, *Dec.*, 15
intravenous urography in, *Dec.*, 6, 16 ff.
split function tests in, *Dec.*, 19 ff.
surgery in, *Dec.*, 22 ff.
atrophy
causes, *Dec.*, 4, 6
urographic diagnosis, *Dec.*, 17
biopsy in diagnosis of disease, *Dec.*, 6
digitalis excretion by, *Nov.*, 8, 13
disease
contraindicating adrenalectomy, *April*, 12
digitalis intoxication in, *Nov.*, 56, 57
with polycythemia, *June*, 50 ff.
function, and polycythemia,

June, 5, 49
function tests
radiorenography, *Dec.*, 9
in unilateral renal disease, *Dec.*, 6 f., 19 ff.
polycystic
detection methods, *Jan.*, 9
heredity in, *Jan.*, 4
vascular areas of, development, *Dec.*, 9
Klinefelter's syndrome, genetic cause, *Jan.*, 16

L

Lanatoside C
dosage schedule, *Nov.*, 7
duration of action, *Nov.*, 9
Larva migrans, visceral, *July*, 16, 18 f.
L.E. factor, in rheumatoid arthritis, *Feb.*, 35 f.
Leukemia
granulocytic
chromosomal abnormality in, *Jan.*, 6
with polycythemia, *June*, 6, 35 f.
involving lung, *July*, 31
lymphocytic, gamma globulin deficiency in, *May*, 29
myeloid, polycythemia with, *June*, 54 f.
radiation-induced, in polycythemia, *June*, 33
Leukocytes
abnormality, inheritance of, *Jan.*, 20
in polycythemia, *June*, 18
Levallorphan, use in newborn, *Oct.*, 12
Liver
complications in polycythemia, *June*, 37 ff.
digitalis metabolism by, *Nov.*, 8, 13 f.
pathology in regional enteritis, *March*, 12
toxic effects of vitamin K on, *Oct.*, 17 ff.
tumors, with polycythemia, *June*, 54
see also Cirrhosis
Lungs
aeration, failure in newborn, *Oct.*, 10
alveolar exchange in polycythemia, *June*, 18
alveolar microlithiasis, *July*, 34
alveolar proteinosis, *July*, 34
biopsy, *July*, 37
circulatory disorders, *July*, 27 f.
collagen disorders, *July*, 25 ff.
disease
digitalis susceptibility in, *Nov.*, 14
occupational, *July*, 23 ff.
polycythemia with, *June*, 43 f.
farmer's, *July*, 23, 25
histiocytoses of, *July*, 36
honeycomb, *July*, 36
x-ray shadows in, *July*, 10, 11
iodized oil retention, *July*, 36 f.
miliary diseases of, *July*, 3 ff.
classification, *July*, 13
collagen diseases causing, *July*, 25 f.
hemosiderosis causing, *July*, 27 f.
infections causing, *July*, 13 ff.
management, *July*, 37 f.
skin tests in, *July*, 38
mucoviscidosis of, *July*, 35
neoplasms of, *July*, 28 ff.
pathology in rheumatoid arthritis, *Feb.*, 6, 13
radiation reaction, *July*, 31 f.
Lupus erythematosus
with auto-immune thyroiditis, *Sept.*, 15
corticosteroids in, *Feb.*, 52
detection methods, *Jan.*, 7
drug therapy, *Feb.*, 54 f.
familial incidence, *Feb.*, 37
joint pathology, *Feb.*, 5
relation to rheumatoid arthritis, *Feb.*, 17 ff.
Lymph node
cellular defects in agammaglobulinemias, *May*, 18 f., 29
transplants, in agammaglobulinemia, *May*, 24, 30
Lymphedema in regional enteritis, *March*, 5, 8 ff.

Lymphoid system
response to antigens, *May*, 12 f.
structure, development of, *May*, 12
tissue changes in rheumatoid arthritis, *Feb.*, 7 f.

M

Malabsorption syndrome
enteritis differentiated from, *March*, 21
after enteritis surgery, *March*, 30
Malaria resistance, genetic factors in, *Jan.*, 5
Malformations, congenital
genetic factors in, *Jan.*, 3, 5
nondisjunction of chromosomal pair causing, *Jan.*, 15 f.
and parental age, *Jan.*, 53
Marie-Strümpell disease. *See* Spondylitis, ankylosing
Meiosis, in genetic transmission, *Jan.*, 15 ff.
Meningitis, *H. influenzae*, therapy in infants, *Oct.*, 40
Mepyrapone, as adrenal inhibitor, *April*, 20 ff.
MER-29. *See* Triparanol
Metabolism
growth hormone effects on, *Aug.*, 13 ff.
inborn errors of
dyshormonogenesis, *Sept.*, 23
as genetic disease, *Jan.*, 4, 14
increased, in polycythemia, *June*, 10
Metaplasia, myeloid, in polycythemia, *June*, 37 ff.
Metazoan infestations, pulmonary, *July*, 16, 18 f.
Methemoglobinemia
carrier detection in, *Jan.*, 26
with polycythemia, *June*, 46
Methylprednisolone, ACTH-suppressing potency, *April*, 6
Metopirone. *See* Mepyrapone
Microlithiasis, alveolar, *July*, 34
Molecular disease, concept of, *Jan.*, 14
Mongolism, genetic cause, *Jan.*, 16
Moniliasis
neonatal, therapy, *Oct.*, 34
pulmonary, *July*, 15
Mononucleosis, infectious, pulmonary involvement, *July*, 21
Mosaic, somatic mutation causing, *Jan.*, 13
Mottling, miliary, of lung, *July*, 8 f.
Mucoviscidosis, involving lungs, *July*, 35
Mutations
chemicals causing, *Jan.*, 44, 46
in genetic material, *Jan.*, 13 ff.
germinal, *Jan.*, 41 ff.
"point," *Jan.*, 13, 41
in population genetics, *Jan.*, 48
radiation causing, *Jan.*, 44 ff.
rate for dominant gene, *Jan.*, 41 f.
rate for recessive trait, *Jan.*, 42
in recessive inheritance, *Jan.*, 22 ff.
somatic, *Jan.*, 13, 43
visible chromosomal, *Jan.*, 13, 41, 43
Mycosis
fungoides, of lung, *July*, 31
pulmonary, causing miliary shadows, *July*, 13, 14 f.
Myeloproliferative disorders, *June*, 5 f.
Myocardium impairment, digitalis sensitivity in, *Nov.*, 53, 57

N

Nalorphine, use in newborn, *Oct.*, 12, 13
Narcotics, causing neonatal apnea, *Oct.*, 12 f.
Neostigmine, in atrial arrhythmias, *Nov.*, 47 f.
Nephrectomy, for renal hypertension, *Dec.*, 22 ff.
Nephrotic syndrome
gamma globulin loss in, *May*, 13
spirolactone in, 28, 30
Nervous system, central
lesions in polycythemia, *June*, 13, 44
symptoms in digitalis intoxication, *Nov.*, 18 f.

Nitrogen mustard
genetic mutation from, Jan., 44
intra-articular use in arthritis, *Feb.*, 53
Nitrogen storage, effect of growth hormone, *Aug.*, 14
Nocardiosis, pulmonary, *July*, 14
Nodules, rheumatoid
subcutaneous, *Feb.*, 7, 8
experimental, *Feb.*, 39
Novobiocin, for infections of newborn, *Oct.*, 33 f.
Nutrition
deficient, and growth retardation, *Aug.*, 31, 32
in regional enteritis, *March*, 17, 29 f.
therapy, *March*, 22 f.
Nystatin, for infections of newborn, *Oct.*, 34 f.

O

Obesity, polycythemia and, *June*, 44
Occupations, lung diseases due to, *July*, 23 ff.
Ornithosis, *July*, 20 ff.
Ouabain
dosage schedule, *Nov.*, 7
duration of action, *Nov.*, 9
Ovaries, cystic, *April*, 9 f.
Oxygen therapy, in newborn, *Oct.*, 14 ff.

P

Paget's disease, with auto-immune thyroiditis, *Sept.*, 16
Palate, cleft, genetic role in, *Jan.*, 5
Pancreas
cystic fibrosis of, *Jan.*, 25
carrier detection in, *Jan.*, 26
mucoviscidosis, *July*, 35
Parahemophilia, carrier detection in, *Jan.*, 27
Paresthesia, in polycythemia, *June*, 10 f.
Penicillin
derivatives, *Oct.*, 36
for neonatal infections, *Oct.*, 35 ff.
sensitivity, in agammaglobulinemia, *May*, 23, 27
with streptomycin, *Oct.*, 38, 39 f.
Pentosuria, carrier detection in, *Jan.*, 27
Phenocopies, and inheritance, *Jan.*, 40
Phenylbutazone
in rheumatoid arthritis, *Feb.*, 44 f.
in spondylitis, *Feb.*, 55
Phenylketonuria, carrier detection in, *Jan.*, 27, 29
Pheochromocytoma
detection methods, *Jan.*, 9
with polycythemia, *June*, 53
Phlebotomy
in anoxic polycythemia, *June*, 49 f.
in polycythemia vera, *June*, 27 f.
with P^{32}, *June*, 29
Pickwickian syndrome, pulmonary insufficiency in, *June*, 44
Pituitary gland
in adrenal hyperplasia, *April*, 11 f.
growth hormone
nature of, *Aug.*, 4 ff.
in regulation of growth, *Aug.*, 18 f.
species specificity of, *Aug.*, 5
insufficiency
etiology, *Aug.*, 27
manifestations, *Aug.*, 27 ff.
mepyrapone test in diagnosis, *April*, 21 f.
treatment, *Aug.*, 34 f.
tumors, in hypersomatotropism, *Aug.*, 35 f., 43
Plague
and blood group antibodies, *Jan.*, 50
involving lungs, *July*, 16, 17
Plasma
factors in polycythemia, *June*, 20 ff., 47 f.
gamma globulin concentration, *May*, 9
in hypogammaglobulinemia, *May*, 14, 33 ff.
Pleiotropism, genetic, *Jan.*, 37, 40 f.
Plethora, in polycythemia, *June*, 5, 13 f.
control of, *June*, 26 f.
Pneumoconiosis, occupational, *July*, 24 f.

Pneumonia
in agammaglobulinemia patients, *May*, 22 f.
aspiration, differentiated from virus, *July*, 20
cold agglutinin, *July*, 20, 21, 22
Friedlander's, *July*, 16, 17
primary atypical, *July*, 19 f.
varicella, *July*, 19, 21, 22
Pneumonitis, irradiation, *July*, 31
Polyarteritis
nodosa, pulmonary, *July*, 25 f.
relation to rheumatoid arthritis, *Feb.*, 18, 19 f.
Polyarthritis
disease types, *Feb.*, 17, 18, 21 ff.
experimental, *Feb.*, 38 f.
as onset of rheumatoid arthritis, *Feb.*, 9
Polycythemia
anoxic, *June*, 42 ff.
etiology, *June*, 43 ff.
symptoms, *June*, 46 ff.
primary, *June*, 4 ff.
relative
from fluid loss, *June*, 56
idiopathic (stress), *June*, 57 f.
types classified, *June*, 3
vera, *June*, 4 ff.
blood values, *June*, 15 ff.
differentiated from anoxic type, *June*, 43
hemosiderosis with, *July*, 27 f.
incidence and etiology, *June*, 4 ff.
life expectancy in, *June*, 35
pathology, *June*, 8
plasma factors, *June*, 20 ff.
symptoms, *June*, 8 ff., 32 f.
treatment, *June*, 26 ff.
Polymorphism, in population genetics, *Jan.*, 48 f.
Polymyxin, for neonatal infections, *Oct.*, 37 f.
Polyposis, multiple, *Jan.*, 8
Porphyria, detection method, *Jan.*, 9
Potassium
administration in newborn, *Oct.*, 20
chloride
in digitalis excess, *Nov.*, 49 f.
intravenous use, *Nov.*, 50 f.
in severe heart failure, *Nov.*, 57
deficiency, *see* Hypokalemia
role in digitalis intoxication, *Nov.*, 14 f.
test of digitalis tolerance, *Nov.*, 46 f.
Prednisolone, ACTH-suppressing potency, *April*, 6
Prednisone
comparative potency, *April*, 5, 6
in regional enteritis, *March*, 26
in rheumatoid arthritis, *Feb.*, 50 f.
Pregnancy
corticosteroid-binding globulin in, *April*, 10
drugs in, effect on fetus, *Oct.*, 41, 44 f.
toxemia, spirolactone in, *April*, 28, 30
Procaine amide, for digitalis-induced arrhythmias, *Nov.*, 51 f.
Prolactin, related to growth hormone, *Aug.*, 5
Prostate, cancer, adrenalectomy in, *April*, 13 f.
Proteinosis, alveolar, *July*, 34 f.
Proteins
metabolism, growth hormone in, *Aug.*, 13 ff.
molecule, genetic alteration, *Jan.*, 14 f.
mutations of, *Jan.*, 13 f.
plasma
electrophoretic separation, *May*, 3 ff.
idiopathic deficit, *May*, 13
serum, in auto-immune thyroiditis, *Sept.*, 17 f., 21
synthesis, DNA in, *Jan.*, 11
Proteus infections, therapy in newborn, *Oct.*, 34
Pruritus, in polycythemia, *June*, 10 f., 33
Pseudohermaphroditism, female, *April*, 8
Pseudomonas infection, therapy in newborn, *Oct.*, 29, 37 f.
Psittacosis, *July*, 20 ff.
Psoriasis, relation to rheumatoid arthritis, *Feb.*, 18, 21 f.

PTA deficiency, carrier detection in, *Jan.*, 27
Puberty
age variability, *Aug.*, 24
precocious
androgens in, *Aug.*, 21
inheritance, *Jan.*, 32
Pyelonephritis
association with hypertension, *Dec.*, 4
intravenous urography in diagnosis, *Dec.*, 6

Q

Q fever, *July*, 20 ff.

R

Radiation
genetic mutations from, *Jan.*, 44 ff.
polycythemia due to, *June*, 6
reaction in lung, *July*, 31 f.
Radiation therapy
for auto-immune thyroiditis, *Sept.*, 24
for pituitary adenoma, *Aug.*, 42 f.
to pituitary, in adrenal hyperfunction, *April*, 12
in polycythemia, *June*, 29 ff.
in regional enteritis, *March*, 26
for splenomegaly, *June*, 40
in spondylitis, *Feb.*, 55
Radiogold, for pituitary adenoma, *Aug.*, 43
Radiography. *See* X-rays
Radioimmunoassay
in acromegaly, *Aug.*, 42
of growth hormone, *Aug.*, 9 f., 11
Radioiodine, uptake in auto-immune thyroiditis, *Sept.*, 19, 20, 27
Radioiron clearance, in polycythemia, *June*, 21 f.
Radiophosphorus
in polycythemia, *June*, 29 f.
in thrombocythemia, *June*, 42
Radiorenography, to detect renal function differences, *Dec.*, 9
Reiter's syndrome, relation to rheumatoid arthritis, *Feb.*, 18, 23 f.
Reserpine, with digitalis, cardiac effect, *Nov.*, 40
Respiration, neonatal
failure to initiate, *Oct.*, 11 f.
failure to maintain, *Oct.*, 13
Retinitis pigmentosa, sex-linked inheritance, *Jan.*, 31
Retinopathy, hypertensive, *Dec.*, 5, 13
Retrolental fibroplasia, in prematures, *Oct.*, 14 ff.
Rheumatism, palindromic, *Feb.*, 25
Rheumatoid factor
in connective tissue diseases, *Feb.*, 18
origin of, *Feb.*, 30 f.
in rheumatoid arthritis, *Feb.*, 18, 26 ff.
in Still's disease, *Feb.*, 14
Rickets, vitamin D-resistant, inheritance, *Jan.*, 32
Rickettsial infections, involving lungs, *July*, 19 ff.
Rothane. *See* DDD

S

Salicylates
for rheumatoid arthritis, *Feb.*, 40 ff.
in rheumatoid-related diseases, *Feb.*, 54 f.
Sarcoidosis
differentiated from berylliosis, *July*, 23 f.
intrathoracic, *July*, 23, 32 f.
x-ray shadows in, *July*, 12
skin test in, *July*, 38
Schistosomiasis, pulmonary, *July*, 18
Scleroderma, relation to rheumatoid arthritis, *Feb.*, 18, 20
Scleromalacia perforans, in rheumatoid arthritis, *Feb.*, 13
Sclerosis, tuberous, of lungs, *July*, 33
Sedation, in digitalis intoxication, *Nov.*, 49
Sickle cell
hemoglobin, genotype, *Jan.*, 12
trait
and genetic disease, *Jan.*, 5
in population, *Jan.*, 49
Silicosis, *July*, 23, 24
Sjögren's syndrome, *July*, 36

Sjögren's syndrome—*Cont'd*
relation to rheumatoid arthritis, *Feb.*, 18, 21
thyroid auto-antibodies in, *Sept.*, 15
Skin
color, inheritance, *Jan.*, 35
erythema, in polycythemia, *June*, 13
hypersensitivity
in agammaglobulinemia, *May*, 23 f.
to digitalis preparations, *Nov.*, 17
tests, in miliary disease of lung, *July*, 38
transplants, in agammaglobulinemia patients, *May*, 24, 30
Smallpox, and blood group antibodies, *Jan.*, 50
Sodium
administration in newborn, *Oct.*, 20, 21
retention
aldosterone role in, *April*, 26
amphenone for, *April*, 19
and edema, adrenalectomy in, *April*, 15
Spherocytosis, hereditary, detection methods, *Jan.*, 8
Spine, in rheumatoid arthritis, *Feb.*, 9, 14
Spirolactone
as adrenal inhibitor, *April*, 23 ff.
as aldosterone antagonist, *April*, 26 ff.
Spironolactone, dosage and side effects, *April*, 30 f.
Splenomegaly, in polycythemia, *June*, 11 f., 14, 38, 41
Spondylitis, ankylosing
management, *Feb.*, 55
relation to rheumatoid arthritis, *Feb.*, 18, 22 f.
uveitis in, *Feb.*, 13
Sporotrichosis, of lung, *July*, 15
Staphylococci, penicillin-resistant
infections in newborn, therapy, *Oct.*, 25 f., 29, 33, 37
of lung, *July*, 16, 17
Stenosis, renal arterial
diagnostic features, *Dec.*, 16 ff.
function tests of individual kidneys in, *Dec.*, 7 f.
and hypertension, *Dec.*, 10 ff.
clinical features, *Dec.*, 12 ff.
medical treatment and results, *Dec.*, 25 ff.
Steroid therapy
in auto-immune thyroiditis, *Sept.*, 24
in dwarfism, *Aug.*, 35
and necrotizing arteritis, *Feb.*, 10 f.
Still's disease, *Feb.*, 13 f., 54
Stimulants, in newborn, *Oct.*, 10 ff.
Streptomycin, for neonatal infections, *Oct.*, 38 ff.
Stress
and disease etiology, *Jan.*, 5, 6
polycythemia, *June*, 57 f.
in regional enteritis, *March*, 7
Strongyloidiasis, pulmonary, *July*, 18
Struma fibrosa, diagnosis, *Sept.*, 23
Struma lymphomatosa. *See* Thyroiditis, auto-immune
SU 4885. *See* Mepyrapone
Sulfation factor
in acromegaly, *Aug.*, 42
changes with age, *Aug.*, 19
in growth hormone assay, *Aug.*, 7, 33
Sulfonamides
in neonatal infections, *Oct.*, 40 f.
in regional enteritis, *March*, 24
Surgery
for auto-immune thyroiditis, *Sept.*, 24
digitalization for, *Nov.*, 57
preoperative prophylactic, *Nov.*, 54
management of patient on corticosteroids, *April*, 6 ff.
for pituitary adenoma, *Aug.*, 43
postoperative susceptibility to digitalis, *Nov.*, 14
for regional enteritis, *March*, 26 ff.
for renal hypertension, *Dec.*, 22 ff.
in rheumatoid arthritis, *Feb.*, 53 f.
risk of, in polycythemia, *June*, 12 f.
Synovium, pathology in rheumatoid arthritis, *Feb.*, 4 f., 14

T

Tachycardia
  atrioventricular nodal, in digitalis excess, *Nov.*, 30 ff.
  paroxysmal atrial
    carotid sinus stimulation in, *Nov.*, 40
    in digitalis excess, *Nov.*, 27 ff.
    procaine amide for, *Nov.*, 51
  sinus, digitalis effect on, *Nov.*, 21
  supraventricular, with bundle branch block, *Nov.*, 38
  ventricular, in digitalis excess, *Nov.*, 35 ff.
Telangiectasia, hemorrhagic, dominant inheritance, *Jan.*, 20
Tetracyclines, in neonatal infections, *Oct.*, 41 f.
Thalassemia
  major, carrier detection in, *Jan.*, 27
  mutations in heredity of, *Jan.*, 39
  and resistance to malaria, *Jan.*, 5
Thrombocythemia, complicating polycythemia, *June*, 41 f.
Thrombocytosis, in polycythemia, *June*, 6 f., 28 f., 31, 41
Thyroglobulin, antibodies in thyroiditis, *Sept.* 4, 5, 6
Thyroid
  auto-antibodies
    detection methods, *Sept.*, 4 ff.
    discovery of, *Sept.*, 4
  cell changes in auto-immune thyroiditis, *Sept.*, 9 f.
  cytotoxic factor in serum, *Sept.*, 7
  disease, antigen-antibody systems in, *Sept.*, 4
  function
    in acromegaly, *Aug.*, 41
    in pituitary dwarfs, *Aug.*, 30
  influence on growth, *Aug.*, 20
  neoplasm, differentiated from auto-immune thyroiditis, *Sept.*, 21 f.
Thyroiditis
  auto-immune, *Sept.*, 3 f., 8 ff.
    diagnostic tests, *Sept.*, 16 ff., 20 ff., 27
    etiology and pathogenesis, *Sept.*, 11 ff.
    history of, *Sept.*, 8 f.
    pathologic anatomy, *Sept.*, 9 ff.
    prevalence of, *Sept.*, 13 f.
    relation to primary hypothyroidism, *Sept.*, 24 f.
    treatment, *Sept.*, 24
  experimental, *Sept.*, 8
  subacute, differentiated from auto-immune, *Sept.*, 22
Thyrotoxicosis
  association of auto-immune thyroiditis and, *Sept.*, 14, 22, 25 f.
  differential diagnosis, *Sept.*, 18 f., 22
  digitalis therapy and, *Nov.*, 57 f.
Thyroxin
  for auto-immune thyroiditis, *Sept.*, 15, 24, 27
  suppression test, in diagnosing auto-immune thyroiditis, *Sept.*, 19
Tomography, in lung disease, *July*, 9
Tooth maturation, as index of growth, *Aug.*, 24
Torulosis, pulmonary, *July*, 14
Toxocara, visceral infestation, *July*, 16 ff.
Transcortin, in adrenal inhibition, *April*, 10 f.
Trauma, in disease etiology, *Jan.*, 4
Triamcinolone, ACTH-suppressing potency, *April*, 6
Triparanol, as adrenal inhibitor, *April*, 22 f.
Tuberculin sensitivity, in agammaglobulinemia, *May*, 24
Tuberculosis, miliary, *July*, 13, 16 f.
  x-ray shadows in, *July*, 8 f., 10, 11
Tularemia
  septicemic, involving lung, *July*, 16, 17
  skin test in, *July*, 38
Tumors
  adenohypophyseal, in hypersomatotropism, *Aug.*, 35 f.
  adrenal, causing hyperfunction, *April*, 11
  causing pituitary insufficiency, *Aug.*, 27
  with polycythemia, *June*, 50 ff.
  in renal artery disease, *Dec.*, 3
Turner's syndrome, *Aug.*, 31, 32

U

Ulcer, peptic
detection methods, *Jan.*, 9
genetic factors in, *Jan.*, 5, 9, 37
in polycythemia, *June*, 11
Urea, infusion in renal stenosis, *Dec.*, 8
Uric acid, in polycythemia serum, *June*, 23 f.
Urinary tract infection
complicating enteritis, *March*, 16 f.
urine culture in, *Dec.*, 6
Urine
concentration tests, in diagnosis, *Dec.*, 6 ff., 20
culture, in diagnosis of infection, *Dec.*, 6
flow reduction, in renal disease, *Dec.*, 20
Urography, intravenous, *Dec.*, 9
in differentiating renal diseases, *Dec.*, 6
in renal artery stenosis, *Dec.*, 16 ff.
Uterus, tumors, with polycythemia, *June*, 51, 53 f.

V

Varicella, involving lungs, *July*, 19, 21, 22
Ventricles
ectopic beats, in digitalis excess, *Nov.*, 31, 35 ff.
See also Arrhythmia
Viral infections
involving lungs, *July*, 19 ff.
resistance in agammaglobulinemia patients, *May*, 17 f., 23, 30
Virilization, in adrenal hyperplasia, *April*, 8
Vision
with digitalis excess, *Nov.*, 18
disturbances in polycythemia, *June*, 9, 14
loss, with pituitary tumors, *Aug.*, 36
Vitamin B_{12}, serum levels in polycythemia, *June*, 21
Vitamin K, in newborn, *Oct.*, 17 ff.

W

Wegener's granulomatosis, *July*, 26
Werner's Syndrome, carrier detection, *Jan.*, 27
v. Willebrand disease, dominant inheritance, *Jan.*, 20
Wilson's disease, carrier detection, *Jan.*, 27
Wolff-Parkinson-White syndrome, digitalis effect in, *Nov.*, 27

X

Xeroderma pigmentosa, carrier detection, *Jan.*, 27
X-rays
correlation with necropsy in hematogenous carcinomatosis, *July*, 29 f.
iodized oil retention in lung, *July*, 36 f.
lung
abnormal shadows, terms to describe, *July*, 8
difficulty of interpretation, *July*, 3 ff., 9 ff.
see also Radiation; Radiation therapy

Y

Yttrium, radioactive, for pituitary tumors, *Aug.*, 43

425

13